R. Hakim, S. Bibi, Q. Ali, Bisma Sarfraz, Y. Arshad, Z. Rehman, M. Salman, A. Ikram, M. Umair
Aim: The current study aimed to identify prevalent dengue serotypes during a major outbreak in 2021 in Pakistan. Materials & methods: From September-November 2021, 373 serum samples from different provinces were tested by RT-PCR for serotype identification, followed by partial sequence analysis of selected dengue-positive samples. Results: Out of 373 samples, 273 (73%) were positive for dengue virus infection with male predominance (61.9%). Complete predominance of DENV-2 serotype (99%) and a single case of DENV-1 was observed. Sequencing data revealed the presence of a cosmopolitan genotype within the DENV-2 Pakistani isolates. Conclusion: This study highlights the persistent predominance of DENV-2 during the 2021 outbreak, suggesting a need to improve surveillance strategies and vector breeding control programs in Pakistan.
{"title":"Molecular epidemiology of dengue virus circulating during 2021 outbreak in Pakistan","authors":"R. Hakim, S. Bibi, Q. Ali, Bisma Sarfraz, Y. Arshad, Z. Rehman, M. Salman, A. Ikram, M. Umair","doi":"10.2217/fvl-2022-0196","DOIUrl":"https://doi.org/10.2217/fvl-2022-0196","url":null,"abstract":"Aim: The current study aimed to identify prevalent dengue serotypes during a major outbreak in 2021 in Pakistan. Materials & methods: From September-November 2021, 373 serum samples from different provinces were tested by RT-PCR for serotype identification, followed by partial sequence analysis of selected dengue-positive samples. Results: Out of 373 samples, 273 (73%) were positive for dengue virus infection with male predominance (61.9%). Complete predominance of DENV-2 serotype (99%) and a single case of DENV-1 was observed. Sequencing data revealed the presence of a cosmopolitan genotype within the DENV-2 Pakistani isolates. Conclusion: This study highlights the persistent predominance of DENV-2 during the 2021 outbreak, suggesting a need to improve surveillance strategies and vector breeding control programs in Pakistan.","PeriodicalId":12505,"journal":{"name":"Future Virology","volume":" ","pages":""},"PeriodicalIF":3.1,"publicationDate":"2023-07-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42850592","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Aim: Epstein–Barr virus-related Burkitt's lymphoma (BL) is characterized by EBNA1 expression. Previous studies have hypothesized a correlation between Burkitt's lymphoma and endemicity of Euphorbia spp. whereas others have suggested it possesses antiviral activity. We aimed to investigate the effect of Euphorbia spp. on BL. Methods: AutoDock Vina, GROMACS 2020.4 and VEGA-QSAR were used for in silico assessments. Results: Daphnoretin had a higher binding affinity than the EBNA1 inhibitor VK0044, maintained a steady ligand RMSD value and displayed the largest negative binding energy at the EBNA1 active site. Conclusion: Daphnoretin, a phytochemical of Euphorbia spp., had superior inhibitory activity of EBNA1 over other tested chemicals, suggesting it is an effective therapeutic drug candidate.
{"title":"Friend or foe: association of Euphorbia spp. with Epstein–Barr virus and Burkitt's lymphoma, an in silico approach","authors":"E. Erdag, Ismet Ersalici, Cenk Serhan Ozverel","doi":"10.2217/fvl-2023-0011","DOIUrl":"https://doi.org/10.2217/fvl-2023-0011","url":null,"abstract":"Aim: Epstein–Barr virus-related Burkitt's lymphoma (BL) is characterized by EBNA1 expression. Previous studies have hypothesized a correlation between Burkitt's lymphoma and endemicity of Euphorbia spp. whereas others have suggested it possesses antiviral activity. We aimed to investigate the effect of Euphorbia spp. on BL. Methods: AutoDock Vina, GROMACS 2020.4 and VEGA-QSAR were used for in silico assessments. Results: Daphnoretin had a higher binding affinity than the EBNA1 inhibitor VK0044, maintained a steady ligand RMSD value and displayed the largest negative binding energy at the EBNA1 active site. Conclusion: Daphnoretin, a phytochemical of Euphorbia spp., had superior inhibitory activity of EBNA1 over other tested chemicals, suggesting it is an effective therapeutic drug candidate.","PeriodicalId":12505,"journal":{"name":"Future Virology","volume":" ","pages":""},"PeriodicalIF":3.1,"publicationDate":"2023-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46463402","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Noorossadat Seyyedi, Fariba Esfandiyari, Gholamreza Rafiei Dehbidi, A. Farhadi, F. Zare, S. Namdari, Golrokh Bahmani, Banafsheh Rastegari, Farzaneh Zarghampoor, A. Behzad-Behbahani
Aim: This study investigated the correlation between anti-thyroid peroxidase (anti-TPO) antibody levels and human herpesvirus 6 (HHV-6) viral load as triggers for Hashimoto's thyroiditis (HT). Materials & methods: The study included 60 HT patients, 60 patients with non-autoimmune thyroid disease, and 60 subjects with normal thyroid function. HHV-6 viral loads in serum samples were detected using real-time PCR. Results: A significant correlation was found between the increase in viral load and increased levels of anti-TPO antibodies in serum samples from HT patients (p = 0.001). Conclusion: The aim of this study was to explore the potential involvement of HHV-6A in the onset of HT, with the goal of identifying improved treatment options for affected individuals.
{"title":"Correlation analysis of HHV-6A viral load and anti-TPO antibody levels in patients with Hashimoto's thyroiditis","authors":"Noorossadat Seyyedi, Fariba Esfandiyari, Gholamreza Rafiei Dehbidi, A. Farhadi, F. Zare, S. Namdari, Golrokh Bahmani, Banafsheh Rastegari, Farzaneh Zarghampoor, A. Behzad-Behbahani","doi":"10.2217/fvl-2022-0194","DOIUrl":"https://doi.org/10.2217/fvl-2022-0194","url":null,"abstract":"Aim: This study investigated the correlation between anti-thyroid peroxidase (anti-TPO) antibody levels and human herpesvirus 6 (HHV-6) viral load as triggers for Hashimoto's thyroiditis (HT). Materials & methods: The study included 60 HT patients, 60 patients with non-autoimmune thyroid disease, and 60 subjects with normal thyroid function. HHV-6 viral loads in serum samples were detected using real-time PCR. Results: A significant correlation was found between the increase in viral load and increased levels of anti-TPO antibodies in serum samples from HT patients (p = 0.001). Conclusion: The aim of this study was to explore the potential involvement of HHV-6A in the onset of HT, with the goal of identifying improved treatment options for affected individuals.","PeriodicalId":12505,"journal":{"name":"Future Virology","volume":" ","pages":""},"PeriodicalIF":3.1,"publicationDate":"2023-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48157034","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
A. Antinori, A. Vergori, D. Ripamonti, D. Valenti, G. Rizzardini, M. Cossu, S. Rusconi, V. Esposito, A. Cascio, G. Orofino, M. Andreoni, E. Manzillo, A. Castagna, D. Mancusi, R. Termini, Marianna Portaro, A. Uglietti
Aim: DIAMANTE is a retrospective and prospective, non-interventional, cohort study to describe the effectiveness of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in real clinical practice in Italy. Patients & methods: The study enrolled 246 patients: group 1 included patients treated with a darunavir-based regimen (n = 81); group 2 included patients who received antiretroviral treatment not including darunavir before D/C/F/TAF (n = 43); and group 3 included naive patients (n = 122). Effectiveness was evaluated as the virological response at week 48. Results: The D/C/F/TAF virological response rate was 72.1–78.8% and was obtained despite longer follow-up intervals due to the coronavirus 2019 pandemic. The safety of D/C/F/TAF was good as was the overall patient satisfaction and quality of life. Conclusion: This study confirmed the effectiveness and tolerability of D/C/F/TAF in a real-life setting both in naive and pretreated patients, with and without darunavir. Clinical Trial Registration: NCT03577470 ( ClinicalTrials.gov )
{"title":"Effectiveness and safety of darunavir/cobicistat/emtricitabine/tenofovir alafenamide therapy in an observational Italian cohort: the DIAMANTE study","authors":"A. Antinori, A. Vergori, D. Ripamonti, D. Valenti, G. Rizzardini, M. Cossu, S. Rusconi, V. Esposito, A. Cascio, G. Orofino, M. Andreoni, E. Manzillo, A. Castagna, D. Mancusi, R. Termini, Marianna Portaro, A. Uglietti","doi":"10.2217/fvl-2023-0065","DOIUrl":"https://doi.org/10.2217/fvl-2023-0065","url":null,"abstract":"Aim: DIAMANTE is a retrospective and prospective, non-interventional, cohort study to describe the effectiveness of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in real clinical practice in Italy. Patients & methods: The study enrolled 246 patients: group 1 included patients treated with a darunavir-based regimen (n = 81); group 2 included patients who received antiretroviral treatment not including darunavir before D/C/F/TAF (n = 43); and group 3 included naive patients (n = 122). Effectiveness was evaluated as the virological response at week 48. Results: The D/C/F/TAF virological response rate was 72.1–78.8% and was obtained despite longer follow-up intervals due to the coronavirus 2019 pandemic. The safety of D/C/F/TAF was good as was the overall patient satisfaction and quality of life. Conclusion: This study confirmed the effectiveness and tolerability of D/C/F/TAF in a real-life setting both in naive and pretreated patients, with and without darunavir. Clinical Trial Registration: NCT03577470 ( ClinicalTrials.gov )","PeriodicalId":12505,"journal":{"name":"Future Virology","volume":" ","pages":""},"PeriodicalIF":3.1,"publicationDate":"2023-06-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41745798","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Ya-Ping Hou, Cheng Fan, Qing-Qing Jiang, Lei Wu, Ying Luo
Aim: Human papillomavirus (HPV) is the most common cause of high-grade lesions and carcinogenesis such as cervical intraepithelial neoplasia (CIN) and cervical cancer (CC). The prevalence and genotype distribution of HPV infection varies greatly in different geographical areas. Patients & methods: This study enrolled 92,932 patients from January 2017 to December 2021 and analyzed the prevalence and distribution of HPV genotypes. Results: 18038 (19.41%) specimens were HPV-positive. No significant difference in infection rates between men and women (19.05 vs 19.41%). The most prevalent HPV subtypes are HPV52, HPV58, HPV16, HPV53, HPV51 and HPV81. Single infection of HPV has dominated in HPV-positive patients. Conclusion: Our results show that the prevalence and distribution of HPV subtypes have obvious region-specific and age-specific characteristics.
{"title":"Prevalence and genotype distribution of human papillomavirus in 92,932 cases in Shanghai, China","authors":"Ya-Ping Hou, Cheng Fan, Qing-Qing Jiang, Lei Wu, Ying Luo","doi":"10.2217/fvl-2022-0180","DOIUrl":"https://doi.org/10.2217/fvl-2022-0180","url":null,"abstract":"Aim: Human papillomavirus (HPV) is the most common cause of high-grade lesions and carcinogenesis such as cervical intraepithelial neoplasia (CIN) and cervical cancer (CC). The prevalence and genotype distribution of HPV infection varies greatly in different geographical areas. Patients & methods: This study enrolled 92,932 patients from January 2017 to December 2021 and analyzed the prevalence and distribution of HPV genotypes. Results: 18038 (19.41%) specimens were HPV-positive. No significant difference in infection rates between men and women (19.05 vs 19.41%). The most prevalent HPV subtypes are HPV52, HPV58, HPV16, HPV53, HPV51 and HPV81. Single infection of HPV has dominated in HPV-positive patients. Conclusion: Our results show that the prevalence and distribution of HPV subtypes have obvious region-specific and age-specific characteristics.","PeriodicalId":12505,"journal":{"name":"Future Virology","volume":" ","pages":""},"PeriodicalIF":3.1,"publicationDate":"2023-06-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42220904","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
S. Ghorbani, Vahid Tambrchi, Rana Farzi, A. Khatami, Rahil Nahid Samiei, H. Saadati, M. Noori, Arash Letafati, Atefeh Bahavar, Noorin Hezarpishe, Mehrshid Musavioun, Bahareh Mirzaei, Mohadeseh Sadat Meftagh, Najme Khodaei Doust, Fatemeh Hejami, S. J. Kiani
Aim: The aim of this study was to investigate the pooled prevalence and potential correlation between Epstein–Barr virus (EBV) infection and brain cancers. Materials & methods: We searched for relevant studies in main databases and analyzed the heterogeneity, odds ratio and corresponding 95% CI among all studies using STATA software V.14. Results: Fourteen articles were included in the meta-analysis. The pooled prevalence of EBV among brain cancer patients was 9% (95% CI: 3–16%; I2 = 91.06%). An association was found between EBV and brain cancer (OR: 6.90 [95% CI: 1.81–26.28]; I2 = 0%]). Conclusion: The results of this study indicate a significant association between EBV infection and brain cancer, suggesting EBV infection is a potential risk factor for brain cancer development.
{"title":"Association between human Epstein–Barr virus and brain cancer: a systematic review and meta-analysis","authors":"S. Ghorbani, Vahid Tambrchi, Rana Farzi, A. Khatami, Rahil Nahid Samiei, H. Saadati, M. Noori, Arash Letafati, Atefeh Bahavar, Noorin Hezarpishe, Mehrshid Musavioun, Bahareh Mirzaei, Mohadeseh Sadat Meftagh, Najme Khodaei Doust, Fatemeh Hejami, S. J. Kiani","doi":"10.2217/fvl-2022-0219","DOIUrl":"https://doi.org/10.2217/fvl-2022-0219","url":null,"abstract":"Aim: The aim of this study was to investigate the pooled prevalence and potential correlation between Epstein–Barr virus (EBV) infection and brain cancers. Materials & methods: We searched for relevant studies in main databases and analyzed the heterogeneity, odds ratio and corresponding 95% CI among all studies using STATA software V.14. Results: Fourteen articles were included in the meta-analysis. The pooled prevalence of EBV among brain cancer patients was 9% (95% CI: 3–16%; I2 = 91.06%). An association was found between EBV and brain cancer (OR: 6.90 [95% CI: 1.81–26.28]; I2 = 0%]). Conclusion: The results of this study indicate a significant association between EBV infection and brain cancer, suggesting EBV infection is a potential risk factor for brain cancer development.","PeriodicalId":12505,"journal":{"name":"Future Virology","volume":" ","pages":""},"PeriodicalIF":3.1,"publicationDate":"2023-06-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46701399","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Aim: The present study aimed to determine a correlation between differential TRIM56 expression levels and severe infections of COVID-19 between the Alpha, Delta and Omicron BA.5 variants.
Materials & methods: This study was performed on 330 COVID-19 patients, including 142 with severe and 188 with mild infections, as well as 160 healthy controls. The levels of TRIM56 gene expression were determined using a qPCR.
Results: TRIM56 gene showed significantly lower mRNA expression in the severe and mild groups compared with healthy individuals. Our finding indicated the high and low reduction of TRIM56 mRNA expression in Delta and Omicron BA.5 variant, respectively.
Conclusion: Further research is needed to characterize the impact of TRIM proteins on the severity of COVID-19.
{"title":"Expression of <i>TRIM56</i> gene in SARS-CoV-2 variants and its relationship with progression of COVID-19.","authors":"Rezvan Tavakoli, Pooneh Rahimi, Mojtaba Hamidi-Fard, Sana Eybpoosh, Delaram Doroud, Iraj Ahmadi, Enayat Anvari, Mohammadreza Aghasadeghi, Abolfazl Fateh","doi":"10.2217/fvl-2022-0210","DOIUrl":"10.2217/fvl-2022-0210","url":null,"abstract":"<p><strong>Aim: </strong>The present study aimed to determine a correlation between differential <i>TRIM56</i> expression levels and severe infections of COVID-19 between the Alpha, Delta and Omicron BA.5 variants.</p><p><strong>Materials & methods: </strong>This study was performed on 330 COVID-19 patients, including 142 with severe and 188 with mild infections, as well as 160 healthy controls. The levels of <i>TRIM56</i> gene expression were determined using a qPCR.</p><p><strong>Results: </strong><i>TRIM56</i> gene showed significantly lower mRNA expression in the severe and mild groups compared with healthy individuals. Our finding indicated the high and low reduction of <i>TRIM56</i> mRNA expression in Delta and Omicron BA.5 variant, respectively.</p><p><strong>Conclusion: </strong>Further research is needed to characterize the impact of TRIM proteins on the severity of COVID-19.</p>","PeriodicalId":12505,"journal":{"name":"Future Virology","volume":"1 1","pages":"563-574"},"PeriodicalIF":3.1,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10348059/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41610222","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Phage treatment has again risen in popularity due to the rise of antibiotic resistance and the need for more reliable alternatives. Human approval of phage therapy has been delayed despite several promising investigations, so, in order to break into the clinical market, existing barriers must be eliminated, and new solutions must be developed. As such, nanotechnology has the potential to help phage formulations overcome their pharmacological drawbacks. The use of nanotechnology to improve phage therapy has received surprisingly little attention in the literature. The key method for increasing phage stability and retention inside the body is encapsulation. New developments in phage therapy using nanotechnology are summarized in this paper.
{"title":"The role of nanotechnology in overcoming barriers to phage therapy: an overview","authors":"Mehrdad Mohammadi, Mehrisadat Mirabadi, Masoumeh Beig, Somaieh Nasereslami, Mina Yazdanmehr, Fatemeh Monfared","doi":"10.2217/fvl-2022-0229","DOIUrl":"https://doi.org/10.2217/fvl-2022-0229","url":null,"abstract":"Phage treatment has again risen in popularity due to the rise of antibiotic resistance and the need for more reliable alternatives. Human approval of phage therapy has been delayed despite several promising investigations, so, in order to break into the clinical market, existing barriers must be eliminated, and new solutions must be developed. As such, nanotechnology has the potential to help phage formulations overcome their pharmacological drawbacks. The use of nanotechnology to improve phage therapy has received surprisingly little attention in the literature. The key method for increasing phage stability and retention inside the body is encapsulation. New developments in phage therapy using nanotechnology are summarized in this paper.","PeriodicalId":12505,"journal":{"name":"Future Virology","volume":" ","pages":""},"PeriodicalIF":3.1,"publicationDate":"2023-05-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43807882","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Bader Y. Alhatlani, Waleed Aljabr, F. Alhamlan, A. Almatroudi, M. Azam, M. Alsaleem, K. Allemailem
Aim: The aim of this study was to identify host factors that interact with the 5′ end of the MERS-CoV RNA genome. Materials & methods: RNA affinity chromatography followed by mass spectrometry analysis was used to identify the binding of host factors in Vero E6 cells. Results: A total of 59 host factors that bound the MERS-CoV RNA genome in non-infected Vero E6 cells were identified. Most of the identified cellular proteins were previously reported to interact with the genome of other RNA viruses. We validated our mass spectrometry results using western blotting. Conclusion: These data enhance our knowledge about the RNA–host interactions of coronaviruses, which could serve as targets for developing antiviral therapeutics against MERS-CoV.
{"title":"Identification of host factors that bind to the 5′ end of the MERS-CoV RNA genome","authors":"Bader Y. Alhatlani, Waleed Aljabr, F. Alhamlan, A. Almatroudi, M. Azam, M. Alsaleem, K. Allemailem","doi":"10.2217/fvl-2023-0070","DOIUrl":"https://doi.org/10.2217/fvl-2023-0070","url":null,"abstract":"Aim: The aim of this study was to identify host factors that interact with the 5′ end of the MERS-CoV RNA genome. Materials & methods: RNA affinity chromatography followed by mass spectrometry analysis was used to identify the binding of host factors in Vero E6 cells. Results: A total of 59 host factors that bound the MERS-CoV RNA genome in non-infected Vero E6 cells were identified. Most of the identified cellular proteins were previously reported to interact with the genome of other RNA viruses. We validated our mass spectrometry results using western blotting. Conclusion: These data enhance our knowledge about the RNA–host interactions of coronaviruses, which could serve as targets for developing antiviral therapeutics against MERS-CoV.","PeriodicalId":12505,"journal":{"name":"Future Virology","volume":" ","pages":""},"PeriodicalIF":3.1,"publicationDate":"2023-05-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48682635","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}